Simon Puttick

Biodegradable core crosslinked star polymer nanoparticles as 19F MRI contrast agents for selective imaging

With the aim of developing stimuli-responsive imaging agents, we report here the synthesis of core crosslinked star (CCS) polymers and their evaluation as pH-sensitive 19F magnetic resonance imaging (19F MRI) contrast agents. Block copolymers consisting of poly(ethylene glycol)methyl ether methacrylate (PPEGMA) as the first block and a copolymer of 2-(dimethylamino)ethyl methacrylate (DMAEMA) and 2,2,2-trifluoroethyl methacrylate (TFEMA) as the second block were synthesised using RAFT polymerisation. The polymerisation kinetics were studied in detail. The block copolymers were then used as arm precursors for the arm-first synthesis of CCS polymers through RAFT dispersion polymerisation. The synthetic conditions were investigated and optimised. CCS polymers with a degradable core were also synthesised and evaluated as 19F MRI contrast agents. The degradation of the core was confirmed by treatment with various reducing agents. The particle size, 19F NMR signal and relaxation times as well as 19F MRI imaging performance of the CCS polymers were studied at a range of value of solution pH. Significant enhancement of the image intensity was observed when the pH was decreased from 8 to 5, indicating that the CCS nanoparticles could be used as 19F MRI contrast agents for the detection of the acidic environment within tumour tissue.

Hypoxia Imaging in Gliomas With 18F-Fluoromisonidazole PET: Toward Clinical Translation

There is significant interest in the development of improved image-guided therapy for neuro-oncology applications. Glioblastomas (GBM) in particular present a considerable challenge because of their pervasive nature, propensity for recurrence, and resistance to conventional therapies. MRI is routinely used as a guide for planning treatment strategies. However, this imaging modality is not able to provide images that clearly delineate tumor boundaries and affords only indirect information about key tumor pathophysiology. With the emergence of PET imaging with new oncology radiotracers, mapping of tumor infiltration and other important molecular events such as hypoxia is now feasible within the clinical setting. In particular, the importance of imaging hypoxia levels within the tumoral microenvironment is gathering interest, as hypoxia is known to play a central role in glioma pathogenesis and resistance to treatment. One of the hypoxia radiotracers known for its clinical utility is (18)F-fluoromisodazole ((18)F-FMISO). In this review, we highlight the typical causes of treatment failure in gliomas that may be linked to hypoxia and outline current methods for the detection of hypoxia. We also provide an overview of the growing body of studies focusing on the clinical translation of (18)F-FMISO PET imaging, strengthening the argument for the use of (18)F-FMISO hypoxia imaging to help optimize and guide treatment strategies for patients with glioblastoma.

PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma.

Glioma is the most aggressive brain tumour, resulting in death often within 1-2 years. Current treatment strategies involve surgical resection followed by chemoradiation therapy. Despite continuing improvements in the delivery of adjuvant therapies, there has not been a dramatic increase in survival for glioma. Molecular imaging techniques have become central in the development of new therapeutic strategies in recent years. The multimodal imaging technology of positron emission tomography/magnetic resonance imaging (PET/MRI) has recently been realised on a preclinical scale and the effect of this technology is starting to be observed in preclinical drug development for glioma. Here, we propose that PET/MRI will play an integral part in the development of new diagnostic and therapeutic strategies for glioma.

Segmented Highly Branched Copolymers: Rationally Designed Macromolecules for Improved and Tunable 19F MRI

Highly branched polymers are a promising platform for the design of next-generation contrast agents for (19)F magnetic resonance imaging (MRI). A series of segmented highly branched polymers (SHBPs) consisting of fluoro- and PEG-based monomers were synthesized by self-condensing vinyl copolymerization (SCVP) using the reversible addition-fragmentation chain transfer (RAFT) technique. SHBPs having different compositions and degrees of branching were obtained by varying the monomer type and feed ratio of monomer to chain transfer agent (CTA). The chemical structures and physical properties of the branched polymers were thoroughly characterized in detail by NMR, SEC and DSC. The systematic variation in structural parameters allowed the relationships between molecular structure, sequence distribution, and imaging performance to be examined. The (19)F NMR properties were strongly affected by the sequence distribution of the fluorinated monomers, the type of polymer backbone and the degree of branching. As a result, SHBPs consisting of statistical copolymeric segments of acrylate units were identified as excellent candidates for imaging due to a single (19)F signal, long T2 relaxation times, and high fluorine contents. The SHBPs could be all imaged or selectively imaged by taking advantage of the differences in relaxation times, demonstrating tunable and selective imaging performance through tailoring the structure and composition of the SHBPs.

Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma

INTRODUCTION Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with (18)F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of (18)F-DOPA imaging grants utility for a number of clinical applications. METHODS A collection of published work about (18)F-FDOPA PET was made and a critical review was discussed and written. RESULTS A number of research papers have been published demonstrating that in conjunction with MRI, (18)F-FDOPA PET provides greater sensitivity and specificity than these modalities in detection, grading, prognosis and validation of treatment success in both primary and recurrent gliomas. In further comparisons with (11)C-MET, (18)F-FLT, (18)F-FET and MRI, (18)F-FDOPA has shown similar or better efficacy. Recently synthesis cassettes have become available, making (18)F-FDOPA more accessible. CONCLUSIONS According to the available data, (18)F-FDOPA PET is a viable radiotracer for imaging and treatment planning of gliomas. ADVANCES IN KNOWLEDGE AND IMPLICATION FOR PATIENT CARE (18)F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis and treatment planning of gliomas cases, improving on that of MRI and (18)F-FDG PET.

Right Ventricular Dysfunction in the R6/2 Transgenic Mouse Model of Huntington's Disease is Unmasked by Dobutamine

BACKGROUND Increasingly, evidence from studies in both animal models and patients suggests that cardiovascular dysfunction is important in HD. Previous studies measuring function of the left ventricle (LV) in the R6/2 model have found a clear cardiac abnormality, albeit with preserved LV systolic function. It was hypothesized that an impairment of RV function might play a role in this condition via mechanisms of ventricular interdependence. OBJECTIVE To investigate RV function in the R6/2 mouse model of Huntingtons disease (HD). METHODS Cardiac cine-magnetic resonance imaging (MRI) was used to determine functional parameters in R6/2 mice. In a first experiment, these parameters were derived longitudinally to determine deterioration of cardiac function with disease progression. A second experiment compared the response to a stress test (using dobutamine) of wildtype and early-symptomatic R6/2 mice. RESULTS There was progressive deterioration of RV systolic function with age in R6/2 mice. Furthermore, beta-adrenergic stimulation with dobutamine revealed RV dysfunction in R6/2 mice before any overt symptoms of the disease were apparent. CONCLUSIONS This work adds to accumulating evidence of cardiovascular dysfunction in R6/2 mice, describing for the first time the involvement of the right ventricle. Cardiovascular dysfunction should be considered, both when treatment strategies are being designed, and when searching for biomarkers for HD.

Multifunctional hyperbranched polymers for CT/19F MRI bimodal molecular imaging

To develop novel contrast agents for bimodal molecular imaging, we report here the design and synthesis of multifunctional hyperbranched polymers containing iodine and fluorine and their application as CT/19F MRI bimodal imaging contrast agents. A hyperbranched iodopolymer (HBIP), which was composed of 2-(2′,3′,5′-triiodobenzoyl)ethyl methacrylate (TIBMA), poly(ethylene glycol) methyl ether methacrylate (PEGMA) and a degradable crosslinker, was first synthesised by reversible addition–fragmentation chain transfer (RAFT) polymerization. Then the HBIP was chain extended with PEGMA and 2,2,2-trifluoroethyl acrylate (TFEA) to form hyperbranched iodopolymers containing 19F (HBIPFs). A series of HBIPFs with different contents of iodine and fluorine were prepared. Nanoparticles with diameters of 10–15 nm were formed by direct dissolution of HBIPFs in water, and the biodegradability was revealed by the treatment of reducing agents. The radio-opacity of these nanoparticles in aqueous solution was confirmed by in vitro CT experiments, and solutions of the nanoparticles were visualised by 19F MRI. These results suggest that the HBIPFs are attractive candidates for CT/19F MRI bimodal imaging.

The influence of domain segregation in ionic liquids upon controlled polymerisation mechanisms: RAFT polymerisation

Recent evidence has suggested that the solvent environment in ionic liquids is dynamic and composed of polar and non-polar domains governed by the summation of weak interactions and self-assembly. Consequently, the effect of a nano-structured solvent environment on chemistries conducted in ionic liquids is coming under increased scrutiny. In this work we investigate how the domain-like structure of ionic liquids affects the kinetics and products of the reversible addition fragmentation chain transfer (RAFT) controlled free radical polymerisation (FRP) of methyl methacrylate in a number of room temperature ionic liquids. By utilising rotating frame Overhauser effect spectroscopy (ROESY) to probe the solvation environment of the 2-cyano prop-2-yl dithiobenzoate (CPDB) RAFT agent, we show that in almost all cases preferential partitioning of the dithiobenzoate-moiety of the RAFT agent into the ionic domain of the ionic liquid occurs.

EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study

Noninvasive imaging is a critical technology for diagnosis, classification, and subsequent treatment planning for patients with glioblastoma. It has been shown that the EphA2 receptor tyrosine kinase (RTK) is overexpressed in a number of tumors, including glioblastoma. Expression levels of Eph RTKs have been linked to tumor progression, metastatic spread, and poor patient prognosis. As EphA2 is expressed at low levels in normal neural tissues, this protein represents an attractive imaging target for delineation of tumor infiltration, providing an improved platform for image-guided therapy. In this study, EphA2-4B3, a monoclonal antibody specific to human EphA2, was labeled with 64Cu through conjugation to the chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). The resulting complex was used as a positron emission tomography (PET) tracer for the acquisition of high-resolution longitudinal PET/magnetic resonance images. EphA2-4B3-NOTA-64Cu images were qualitatively and quantitatively compared to the current clinical standards of [18F]FDOPA and gadolinium (Gd) contrast–enhanced MRI. We show that EphA2-4B3-NOTA-64Cu effectively delineates tumor boundaries in three different mouse models of glioblastoma. Tumor to brain contrast is significantly higher in EphA2-4B3-NOTA-64Cu images than in [18F]FDOPA images and Gd contrast–enhanced MRI. Furthermore, we show that nonspecific uptake in the liver and spleen can be effectively blocked by a dose of nonspecific (isotype control) IgG.

Novel Gd-Loaded Silicon Nanohybrid: A Potential Epidermal Growth Factor Receptor Expressing Cancer Cell Targeting Magnetic Resonance Imaging Contrast Agent

Continuing our research efforts in developing mesoporous silicon nanoparticle-based biomaterials for cancer therapy, we employed here porous silicon nanoparticles as a nanocarrier to deliver contrast agents to diseased cells. Nanoconfinement of small molecule Gd-chelates (L1-Gd) enhanced the T1 contrast dramatically compared to distinct Gd-chelate (L1-Gd) by virtue of its slow tumbling rate, increased number of bound water molecules, and their occupancy time. The newly synthesized Gd-chelate (L1-Gd) was covalently grafted on silicon nanostructures and conjugated to an antibody specific for epidermal growth factor receptor (EGFR) via a hydrazone linkage. The salient feature of this nanosized contrast agent is the capability of EGFR targeted delivery to cancer cells. Mesoporous silicon nanoparticles were chosen as the nanocarrier because of their high porosity, high surface area, and excellent biodegradability. This type of nanosized contrast agent also performs well in high magnetic fields.